Urgent.News

What's breaking now, across hundreds of outlets.

Finance & Markets

Novo Nordisk's Wegovy Pill Is Capturing 80% of New Oral Obesity Prescriptions. Is NVO Stock a Buy?

Key PointsNovo Nordisk was the first to market with a GLP-1 weight-loss shot, but lost its lead to Eli Lilly.

We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.

This story

This is one outlet's version. Read the fullest account.

Every outlet that reported this, and when →

Read the original at nasdaq.com →

Report a problem with this story

More in Finance & Markets

iQiyi: 3 Key Takeaways for Long-Term Investors

Shifting content costs onto creators via revenue sharing leaves iQiyi's hit-driven model in question as AI production scales.

  • iQiyi shifts content creation to revenue sharing with third-party creators
  • AI-generated content accelerates transformation of intellectual property
  • Short-form dramas dominate market share in rapidly growing category

More from Saturday 21 November →